On February 13, Hang Seng Indexes Company announced the results of its quarterly review of the Hang Seng Index Series as of December 31, 2025. XuanZhu Bio-B (02575) has been included in the Hang Seng Composite Index. The changes will take effect after the market close on Friday, March 6, 2026, and will be implemented starting Monday, March 9, 2026. Following this, the Shanghai and Shenzhen stock exchanges are expected to adjust the list of eligible stocks under the Hong Kong Stock Connect program accordingly. According to a CICC research report, XuanZhu Bio-B is likely to be added to the Stock Connect scheme, as it meets a range of criteria including market capitalization, liquidity, and listing duration. On December 7, 2025, the National Healthcare Security Administration released the updated National Reimbursement Drug List for 2025. XuanZhu Bio-B’s self-developed Class 1 innovative drug, the CDK4/6 inhibitor Piroxiclib Tablets, was successfully included in the list, providing new reimbursement benefits for patients with advanced breast cancer.